Billie Odom, MD
Neurology · Bloomington, INNPI 1790246676
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Biogen at 24.2% of the total. That places this record below the midpoint for neurology clinicians in IN, where the typical reported total is $1,614.
Across 58 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$269
- AbbVie$266
- Takeda Pharmaceuticals U.S.A., Inc.$95
- Neurocrine Biosciences, Inc.$91
- Argenx US, Inc.$87
- UCB, Inc.$75
- plus $226 from 8 others
What the payments were for
- Food & beverage$1,109100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 14 | $269 |
| AbbVie | 18 | $266 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $95 |
| Neurocrine Biosciences, Inc. | 5 | $91 |
| Argenx US, Inc. | 4 | $87 |
| UCB, Inc. | 3 | $75 |
| Lilly USA, LLC | 2 | $48 |
| Johnson & Johnson | 2 | $39 |
| AstraZeneca | 2 | $38 |
| Aucta Pharmaceuticals, Inc. | 1 | $30 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $16 |
How this compares
$1,109 in reported general payments places this provider in the 40th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 12 | $1,447 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 77 | $1,235 |
| Levetiracetam | 67 | $1,204 |
| Memantine Hcl | 30 | $1,201 |
| Donepezil Hcl | 70 | $931 |
| Primidone | 42 | $666 |
| Gabapentin | 29 | $661 |
| Lacosamide | 12 | $626 |
| Propranolol Hcl | 26 | $519 |
| Topiramate | 37 | $469 |
| Sumatriptan Succinate | 22 | $283 |
| Pregabalin | 14 | $217 |
| Lamotrigine | 19 | $197 |
| Propranolol Hcl ErPropranolol Hcl | 13 | $196 |
| Atorvastatin Calcium | 17 | $187 |
Paid to pharmacies, not to this prescriber.
Other neurology in Bloomington
- Sharisse StephensonBloomington$23K
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.